This study describes the characteristics of high drug-cost beneficiaries (the top 5% of public drug program beneficiaries based on annual costs) in 9 provinces across Canada, to inform current planning around national drug strategies.
This study explores whether oxycodone and hydromorphone are differentially associated with suicide.
Current and prospective utilization of innovator biologics and biosimilars in Ontario
This report describes the current and prospective utilization patterns and expenditures of innovator biologics and biosimilars through the public drug program in Ontario, Canada.
This study evaluates the impact of both the private availability of a live attenuated vaccine for herpes zoster and the introduction of an associated publicly funded immunization program on the burden of herpes zoster among Ontario residents.
Understanding the implications of a shifting opioid landscape in Ontario
This report describes changing patterns of opioid prescribing in Ontario and their role in fatal opioid overdoses to inform future policy decisions.